A 802715

Drug Profile

A 802715

Latest Information Update: 03 Jul 2002

Price : $50

At a glance

  • Originator Aventis
  • Class Small molecules
  • Mechanism of Action Cytokine inhibitors; T lymphocyte inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Septic shock; Transplant rejection

Most Recent Events

  • 24 Dec 1999 Hoechst Marion Roussel has merged with Rhône-Poulenc Rorer to form Aventis Pharma
  • 23 Sep 1997 Data have been added to the Pharmacodynamic section for Transplant Rejection ,
  • 11 Feb 1997 Preclinical development for Septic shock in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top